A 64-year-old patient with extremely high number of white blood cells was diagnosed with T prolymphocytic leukemia. After the initiation of chemotherapy with Cyclophosphamide, Oncovin, Doxorubicin and Prednisone (CHOP), there was no improvement and the patient died within two months. Authors have made a review of the current therapy of this rare disorder of mature T-lymphocytes and discussed various therapeutic aspects of hyperlymphocytosis.
Matutes E, Brito-Babapulle V, Swansbury J, Ellis J, Morilla R, Dearden C, et al. Clinical and Laboratory Features of 78 Cases of T Prolymphocytic Leukemia. Blood. 1991;78:3269–74.
Porcu P, Cripe L, Ng EW. Hyperleukocytic leukae mia and leukostasis: A review of pathophysiology, clini cal presentation and management. Leuk Lymphoma. 2000;39:1–18.
6.
Savć I. Terapijski efekat vitamina e kao farmakoreolo škog lekaianti-oksidanta na reološke osobine eritrocita u pacijenata sa akutnom leukemijom. Acta Facultatis Med Naissensis. 2002;19Č:102–6.
7.
Billio A, Pescosta N, Rosanelli C, Fabris P, Coser P. A brief intensive chemotherapy in T-prolymphocytic leu kemia Haematologica. 2000;85:438–9.
8.
Mercieca J, Matutes E, Dearden C, Mac Lennan K, D C. The role of pentostatin in the treatment of T cell malignancies: analysis of response rate in 145 patients according to disease subtype. J Clin Oncol. 1994;12:2588–93.
9.
Keating MJ, Cazin B, S C. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol. 2002;20:205–13.
10.
Robak T, Robak P. Current treatment options in proly mphocytic leukaemia. Med Sci Monit. 2007;13:69 80.
11.
Marjanović G, Todorović-Bakrač M, Jevtović-Stoimenov T. Cord Blood Transplantation in Adult Patients With Hematological Malignancies. Acta Facultatis Med Nai ssensis. 2010;27:215–20.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
